Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alcoholic Hepatitis Clear all
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

NCT00063232
View directory record Official record
Conditions
Hepatitis
Interventions
Metformin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 28, 2026, 8:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of F-652 in Patients With Alcoholic Hepatitis

NCT02655510
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
F-652
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 28, 2026, 8:16 AM EDT
Withdrawn Early Phase 1 Interventional

Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

NCT03087968
View directory record Official record
Conditions
Severe Alcoholic Hepatitis
Interventions
GS-4997, Prednisolone, HepQuant SHUNT Test, Placebo
Drug · Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Coronado, California • Miami, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Sep 28, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

NCT02083367
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 28, 2026, 8:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis

NCT04088370
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Blood Draw
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 8:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 28, 2026, 8:16 AM EDT
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 28, 2026, 8:16 AM EDT
Completed Phase 4 Interventional

Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

NCT00160407
View directory record Official record
Conditions
Fatty Liver, Hepatitis
Interventions
Orlistat (Xenical), 1400 kcal diet (30% fat)
Drug · Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
St Louis, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Sep 28, 2026, 8:16 AM EDT
Completed No phase listed Observational

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

NCT05669677
View directory record Official record
Conditions
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD, NASH
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 8:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 8:16 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Alcohol-Related Hepatitis With Arginine

NCT00200746
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Arginine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Sep 28, 2026, 8:16 AM EDT
Completed No phase listed Observational

Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis

NCT02075918
View directory record Official record
Conditions
Alcoholic Hepatitis, Control Patients
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 28, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

NCT01747772
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
Interventions
Shear Wave Sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 28, 2026, 8:16 AM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 8:16 AM EDT
Completed No phase listed Observational

Outcomes Using MARS for Patients With ALF

NCT05594953
View directory record Official record
Conditions
Alcoholic Hepatitis, Acute Liver Failure
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 28, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis

NCT01968382
View directory record Official record
Conditions
Hepatitis, Alcoholic
Interventions
IMM 124-E (Hyperimmune Bovine Colostrum), Placebo (High protein milk powder)
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Indianapolis, Indiana • Rochester, Minnesota • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 28, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

NCT04563026
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 28, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

Pegfilgrastim in Patients With Alcoholic Hepatitis

NCT02776059
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Standard of care + pegfiltrastim, Standard of care
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Loma Linda, California • Long Beach, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 28, 2026, 8:16 AM EDT
Recruiting Not applicable Interventional

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

NCT03845205
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Hepatitis
Interventions
Integrated AUD Treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 28, 2026, 8:16 AM EDT
Terminated Phase 3 Interventional Results available

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

NCT01829347
View directory record Official record
Conditions
Severe Acute Alcoholic Hepatitis
Interventions
ELAD, Standard of Care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 28, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

NCT05639543
View directory record Official record
Conditions
Alcohol Associated Hepatitis
Interventions
INT-787, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 28, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

NCT01937130
View directory record Official record
Conditions
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 28, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

NCT03452540
View directory record Official record
Conditions
Severe Acute Decompensated Alcoholic Hepatitis
Interventions
1000mg DS102 (BID)
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Miami, Florida • Kansas City, Kansas • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 28, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121
View directory record Official record
Conditions
Liver Diseases, Hypertension, Portal
Interventions
Avenciguat, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 28, 2026, 8:16 AM EDT